1887

Abstract

Neutralizing antibodies have been widely used for the prophylaxis and treatment of COVID-19.

The major target for these neutralizing antibodies is the receptor-binding domain (RBD) of the viral spike protein.

In the present study, we developed and characterized three neutralizing chimeric mouse-human mAbs for potential therapeutic purposes.

Light and heavy chain variable region genes of three mouse mAbs (m4E8, m3B6, and m1D1) were amplified and ligated to human Cγ1 and Cκ constant region genes by PCR. After cloning into a dual promoter mammalian expression vector, the final constructs were transiently expressed in DG-44 cells and the purified chimeric antibodies were characterized by ELISA and Western blotting. The neutralizing potency of the chimeric mAbs was determined by three different virus neutralization tests including sVNT, pVNT, and cVNT.

All three recombinant chimeric mAbs display human constant regions and are able to specifically bind to the RBD of SARS-CoV-2 with affinities comparable to the parental mAbs. Western blot analysis showed similar epitope specificity profiles for both the chimeric and the parental mouse mAbs. The results of virus neutralization tests (sVNT, pVNT, and cVNT) indicate that c4E8 had the most potent neutralizing activity with IC50 values of 1.772, 0.009, and 0.01 µg ml, respectively. All chimeric and mouse mAbs displayed a similar pattern of reactivity with the spike protein of the SARS-CoV-2 variants of concern (VOC) tested, including alpha, delta, and wild-type.

The chimeric mAbs displayed neutralizing potency similar to the parental mouse mAbs and are potentially valuable tools for disease control.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. The Microbiology Society waived the open access fees for this article.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001728
2023-06-30
2024-06-25
Loading full text...

Full text loading...

/deliver/fulltext/jmm/72/6/jmm001728.html?itemId=/content/journal/jmm/10.1099/jmm.0.001728&mimeType=html&fmt=ahah

References

  1. Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2. Int J Biol Sci 2020; 16:1718–1723 [View Article] [PubMed]
    [Google Scholar]
  2. Hanke L, Vidakovics Perez L, Sheward DJ, Das H, Schulte T et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat Commun 2020; 11:4420 [View Article] [PubMed]
    [Google Scholar]
  3. Deb P, Molla MMA, Saif-Ur-Rahman KM. An update to monoclonal antibody as therapeutic option against COVID-19. Biosaf Health 2021; 3:87–91 [View Article] [PubMed]
    [Google Scholar]
  4. WHO Coronavirus (COVID-19) Dashboard. n.d https://covid19.who.int/ accessed 31 January 2033
  5. Liu L, Wang P, Nair MS, Yu J, Rapp M et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020; 584:450–456 [View Article] [PubMed]
    [Google Scholar]
  6. Chi X, Liu X, Wang C, Zhang X, Li X et al. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat Commun 2020; 11:4528 [View Article] [PubMed]
    [Google Scholar]
  7. Maghsood F, Ghorbani A, Yadegari H, Golsaz-Shirazi F, Amiri MM et al. SARS-CoV-2 nucleocapsid: Biological functions and implication for disease diagnosis and vaccine design. Rev Med Virol 2023; 33:e2431 [View Article] [PubMed]
    [Google Scholar]
  8. Yu F, Xiang R, Deng X, Wang L, Yu Z et al. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduct Target Ther 2020; 5:212 [View Article] [PubMed]
    [Google Scholar]
  9. Ehteshaminia Y, Jalali SF, Jadidi-Niaragh F, Enderami SE, Pagheh AS et al. Enhancement of immunogenicity and neutralizing responses against SARS-CoV-2 spike protein using the Fc fusion fragment. Life Sci 2023; 320:121525 [View Article] [PubMed]
    [Google Scholar]
  10. Yadegari H, Mohammadi M, Maghsood F, Ghorbani A, Bahadori T et al. Diagnostic performance of a novel antigen-capture ELISA for the detection of SARS-CoV-2. Anal Biochem 2023; 666:115079 [View Article] [PubMed]
    [Google Scholar]
  11. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med 2020; 383:1813–1826 [View Article] [PubMed]
    [Google Scholar]
  12. Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J 2020; 96:550–555 [View Article] [PubMed]
    [Google Scholar]
  13. Monteleone G, Sarzi-Puttini PC, Ardizzone S. Preventing COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatol 2020; 2:e255–e256 [View Article] [PubMed]
    [Google Scholar]
  14. Wen W, Chen C, Tang J, Wang C, Zhou M et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Ann Med 2022; 54:516–523 [View Article] [PubMed]
    [Google Scholar]
  15. Wang C, Li W, Drabek D, Okba NMA, van Haperen R et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 2020; 11:1–6 [View Article]
    [Google Scholar]
  16. Lu R-M, Hwang Y-C, Liu I-J, Lee C-C, Tsai H-Z et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci 2020; 27:1 [View Article] [PubMed]
    [Google Scholar]
  17. Li D, Sempowski GD, Saunders KO, Acharya P, Haynes BF. SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment. Annu Rev Med 2022; 73:1–16 [View Article] [PubMed]
    [Google Scholar]
  18. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2021; 384:229–237 [View Article]
    [Google Scholar]
  19. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021; 384:238–251 [View Article]
    [Google Scholar]
  20. Martin-Blondel G, Marcelin A-G, Soulié C, Kaisaridi S, Lusivika-Nzinga C et al. Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2. J Infect 2022; 85:e104–e108 [View Article] [PubMed]
    [Google Scholar]
  21. Loo Y-M, McTamney PM, Arends RH, Abram ME, Aksyuk AA et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Transl Med 2022; 14:eabl8124 [View Article] [PubMed]
    [Google Scholar]
  22. VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 2022; 28:490–495 [View Article] [PubMed]
    [Google Scholar]
  23. Liu Z, VanBlargan LA, Bloyet L-M, Rothlauf PW, Chen RE et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 2021; 29:477–488 [View Article] [PubMed]
    [Google Scholar]
  24. Widyasari K, Kim J. A review of the currently available antibody therapy for the treatment of coronavirus disease 2019 (COVID-19). Antibodies 2023; 12:5 [View Article] [PubMed]
    [Google Scholar]
  25. Maghsood F, Amiri MM, Zarnani A-H, Salimi V, Kardar GA et al. Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies. Front Med 2022; 9:973036 [View Article] [PubMed]
    [Google Scholar]
  26. Liu AY, Robinson RR, Murray ED, Ledbetter JA, Hellström I et al. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 1987; 139:3521–3526 [View Article] [PubMed]
    [Google Scholar]
  27. Yamin R, Jones AT, Hoffmann H-H, Schäfer A, Kao KS et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature 2021; 599:465–470 [View Article] [PubMed]
    [Google Scholar]
  28. Amiri MM, Bahadori T, Soltantoyeh T, Hosseini-Ghatar R, Golsaz-Shirazi F et al. Development of a novel inhibitory chimeric anti-HER2 monoclonal antibody. Iran J Immunol 2019; 16:26–42 [View Article] [PubMed]
    [Google Scholar]
  29. Mohammadi M, Jeddi-Tehrani M, Golsaz-Shirazi F, Arjmand M, Bahadori T et al. A novel anti-HER2 bispecific antibody with potent tumor inhibitory effects in vitro and in vivo. Front Immunol 2021; 11:600883 [View Article]
    [Google Scholar]
  30. Ghotloo S, Golsaz-Shirazi F, Amiri MM, Jeddi-Tehrani M, Shokri F. Neutralization of tetanus toxin by a novel chimeric monoclonal antibody. Toxicon 2021; 201:27–36 [View Article] [PubMed]
    [Google Scholar]
  31. Amiri MM, Golsaz-Shirazi F, Soltantoyeh T, Hosseini-Ghatar R, Bahadori T et al. Hersintuzumab: a novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition. Invest New Drugs 2018; 36:171–186 [View Article] [PubMed]
    [Google Scholar]
  32. Ferrara F, Temperton N. Pseudotype neutralization assays: from laboratory bench to data aalysis. Methods Protoc 2018; 1:8 [View Article] [PubMed]
    [Google Scholar]
  33. Mira E, Yarce OA, Ortega C, Fernández S, Pascual NM et al. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. J Allergy Clin Immunol Pract 2020; 8:2793–2795 [View Article] [PubMed]
    [Google Scholar]
  34. Amiri MM, Jeddi-Tehrani M, Kazemi T, Bahadori M, Maddah M et al. Construction and characterization of a new chimeric antibody against HER2. Immunotherapy 2013; 5:703–715 [View Article] [PubMed]
    [Google Scholar]
  35. Golsaz-Shirazi F, Amiri MM, Farid S, Bahadori M, Bohne F et al. Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg). Antiviral Res 2017; 144:153–163 [View Article] [PubMed]
    [Google Scholar]
  36. Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade®(Infliximab): 20 years of contributions to science and medicine. Biologics 2019; 13:139
    [Google Scholar]
  37. Keating GM. Rituximab. Drugs 2010; 70:1445–1476 [View Article]
    [Google Scholar]
  38. Zebedee SL, Koduri RK, Mukherjee J, Mukherjee S, Lee S et al. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother 1994; 38:1507–1514 [View Article]
    [Google Scholar]
  39. Preston MJ, Gerçeker AA, Reff ME, Pier GB. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide. Infect Immun 1998; 66:4137–4142 [View Article] [PubMed]
    [Google Scholar]
  40. Thakur V, Ratho RK. OMICRON (B.1.1.529): a new SARS-CoV-2 variant of concern mounting worldwide fear. J Med Virol 2022; 94:1821–1824 [View Article] [PubMed]
    [Google Scholar]
  41. VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 2022; 28:490–495 [View Article] [PubMed]
    [Google Scholar]
  42. Focosi D, Maggi F. Neutralising antibody escape of SARS-CoV-2 spike protein: risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol 2021; 31:e2231 [View Article] [PubMed]
    [Google Scholar]
  43. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B et al. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. MedRxiv 2021 [View Article]
    [Google Scholar]
  44. Cao YR, Wang J, Jian F, Xiao T, Song W et al. B. 1.1. 529 escapes the majority of SARS-Cov-2 neutralizing antibodies of diverse epitopes. BioRxiv 2021 [View Article]
    [Google Scholar]
  45. Cao Y, Yisimayi A, Jian F, Song W, Xiao T et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022; 608:593–602 [View Article]
    [Google Scholar]
  46. Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies. BioRxiv 20222022.11.17.516888 [View Article] [PubMed]
    [Google Scholar]
  47. Riepler L, Rössler A, Falch A, Volland A, Borena W et al. Comparison of four SARS-CoV-2 neutralization assays. Vaccines 2020; 9:13 [View Article] [PubMed]
    [Google Scholar]
  48. von Rhein C, Scholz T, Henss L, Kronstein-Wiedemann R, Schwarz T et al. Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma. J Virol Methods 2021; 288:114031 [View Article] [PubMed]
    [Google Scholar]
  49. Zedan HT, Yassine HM, Al-Sadeq DW, Liu N, Qotba H et al. Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies. Sci Rep 2022; 12:19020 [View Article] [PubMed]
    [Google Scholar]
  50. Bošnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W et al. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell Mol Immunol 2021; 18:936–944 [View Article]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001728
Loading
/content/journal/jmm/10.1099/jmm.0.001728
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error